191 related articles for article (PubMed ID: 19691126)
1. Onset and spread of dyskinesias and motor symptoms in Parkinson's disease.
Fabbrini G; Defazio G; Colosimo C; Suppa A; Bloise M; Berardelli A
Mov Disord; 2009 Oct; 24(14):2091-6. PubMed ID: 19691126
[TBL] [Abstract][Full Text] [Related]
2. Dyskinesias and motor symptoms onset in Parkinson disease.
Latorre A; Bloise MC; Colosimo C; Di Biasio F; Defazio G; Berardelli A; Fabbrini G
Parkinsonism Relat Disord; 2014 Dec; 20(12):1427-9. PubMed ID: 25455693
[TBL] [Abstract][Full Text] [Related]
3. Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease.
Gour J; Edwards R; Lemieux S; Ghassemi M; Jog M; Duval C
Brain Res Bull; 2007 Sep; 74(1-3):66-74. PubMed ID: 17683791
[TBL] [Abstract][Full Text] [Related]
4. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
Fenney A; Jog MS; Duval C
Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
[TBL] [Abstract][Full Text] [Related]
5. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
7. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
[TBL] [Abstract][Full Text] [Related]
8. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
9. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
De Reuck J; De Weweire M; Van Maele G; Santens P
J Neurol Sci; 2005 Apr; 231(1-2):35-9. PubMed ID: 15792818
[TBL] [Abstract][Full Text] [Related]
10. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
[TBL] [Abstract][Full Text] [Related]
11. Impact of the motor complications of Parkinson's disease on the quality of life.
Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
[TBL] [Abstract][Full Text] [Related]
12. Dyskinesia-induced postural instability in Parkinson's disease.
Armand S; Landis T; Sztajzel R; Burkhard PR
Parkinsonism Relat Disord; 2009 Jun; 15(5):359-64. PubMed ID: 18851925
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
[TBL] [Abstract][Full Text] [Related]
14. Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias.
Ghassemi M; Lemieux S; Jog M; Edwards R; Duval C
Brain Res Bull; 2006 May; 69(5):512-8. PubMed ID: 16647580
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
16. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
[TBL] [Abstract][Full Text] [Related]
18. [Risk factors associated with the development of motor complications in Parkinson's disease. A study in a Chilean population].
Juri-Claveria C; Aguirre-M C; Viviani-G P; Chana-Cuevas P
Rev Neurol; 2007 Jul 16-31; 45(2):77-80. PubMed ID: 17642046
[TBL] [Abstract][Full Text] [Related]
19. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
20. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
Doan JB; Melvin KG; Whishaw IQ; Suchowersky O
Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
